Legal & General Group PLC Kodiak Sciences Inc. Transaction History

Legal & General Group PLC

$368 Billion
Q4 2024

A detailed history of Legal & General Group PLC transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 2,747 shares of KOD stock, worth $14,449. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,747

Previous 2,747 -0.0%

Holding current value

$14,449

Previous $7,000 285.71%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.8 - $7.49 $1,024 - $4,261	-569 Reduced 17.16%	2,747 $4,000
Q2 2023 Aug 14, 2023	SELL	$4.3 - $9.48 $13,390 - $29,520	-3,114 Reduced 48.43%	3,316 $22,000
Q1 2023 May 15, 2023	SELL	$4.81 - $8.88 $33,612 - $62,053	-6,988 Reduced 52.08%	6,430 $39,000
Q3 2022 Nov 14, 2022	SELL	$7.57 - $12.5 $107,531 - $177,562	-14,205 Reduced 51.42%	13,418 $104,000
Q2 2022 Aug 22, 2022	SELL	$5.04 - $9.48 $4,626 - $8,702	-918 Reduced 3.22%	27,623 $211,000
Q1 2022 May 16, 2022	BUY	$7.09 - $89.45 $397 - $5,009	56 Added 0.2%	28,541 $220,000
Q4 2021 Feb 14, 2022	BUY	$80.85 - $128.49 $18,838 - $29,938	233 Added 0.82%	28,485 $2.42 Million
Q3 2021 Nov 15, 2021	BUY	$81.97 - $106.94 $489,442 - $638,538	5,971 Added 26.8%	28,252 $2.71 Million
Q2 2021 Aug 12, 2021	BUY	$77.2 - $126.54 $45,470 - $74,532	589 Added 2.72%	22,281 $2.07 Million
Q1 2021 May 17, 2021	BUY	$110.45 - $164.47 $23,304 - $34,703	211 Added 0.98%	21,692 $2.46 Million
Q4 2020 Feb 12, 2021	BUY	$60.78 - $154.03 $1.31 Million - $3.31 Million	21,481 New	21,481 $3.16 Million

Others Institutions Holding KOD

# of Institutions

109

Shares Held

40.9M

Call Options Held

28.4K

Put Options Held

21.2K

View Full List

About Kodiak Sciences Inc.

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $274M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

More about KOD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Kodiak Sciences Inc. Transaction History